These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30652313)

  • 1. Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?
    Benet LZ; Jayachandran P; Carroll KJ; Burmeister Getz E
    Clin Pharmacol Ther; 2019 Feb; 105(2):326-328. PubMed ID: 30652313
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic substitution: issues for problematic drugs.
    Henderson JD; Esham RH
    South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consideration of international generic distribution policies on patient outcomes in the United States and Germany.
    Saverno K; Gothe H; Schuessel K; Biskupiak J; Schulz M; Siebert U; Brixner D
    Pharmazie; 2014 Mar; 69(3):238-40. PubMed ID: 24716417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials.
    Pereira JA; Holbrook AM; Dolovich L; Goldsmith C; Thabane L; Douketis JD; Crowther MA; Bates SM; Ginsberg JS
    Ann Pharmacother; 2005; 39(7-8):1188-93. PubMed ID: 15914517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic Drug Product Development in Japan: Regulatory Updates During 2014-2019 and the Future.
    Kasuga M; Kuribayashi R; Ogawa T; Ugi A; Yamaguchi T; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):711-719. PubMed ID: 34586614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First approval of generic dry powder inhaler drug products in Japan.
    Kuribayashi R; Myoenzono A
    Drug Deliv Transl Res; 2020 Oct; 10(5):1517-1519. PubMed ID: 32613551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity.
    Schellekens H
    Eur J Clin Invest; 2004 Dec; 34(12):797-9. PubMed ID: 15606720
    [No Abstract]   [Full Text] [Related]  

  • 10. Single Batch Bioequivalence Paradigm for Orally Inhaled Products: Time for Change.
    Hermann R; Olsson B; Borgström L; Sandell D
    Clin Pharmacol Ther; 2018 Mar; 103(3):395. PubMed ID: 29238955
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
    Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
    J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
    [No Abstract]   [Full Text] [Related]  

  • 12. Current Understanding of the Equivalence Evaluations for In Vitro Tests on Generic Dry Powder Inhaler Drug Products in Japan.
    Kuribayashi R; Myoenzono A; Takagi K; Hirota M
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):743-745. PubMed ID: 31062276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic anti-arrhythmic drugs.
    Obel IW
    Cardiovasc J S Afr; 2002; 13(3):131; author reply 132-3. PubMed ID: 12193966
    [No Abstract]   [Full Text] [Related]  

  • 14. Substituting warfarin products: what's the source of the problem?
    Haines ST
    Ann Pharmacother; 2011 Jun; 45(6):807-9. PubMed ID: 21666090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.
    Yacobi A; Masson E; Moros D; Ganes D; Lapointe C; Abolfathi Z; LeBel M; Golander Y; Doepner D; Blumberg T; Cohen Y; Levitt B
    J Clin Pharmacol; 2000 Aug; 40(8):826-35. PubMed ID: 10934666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brand name versus generic warfarin: a systematic review of the literature.
    Dentali F; Donadini MP; Clark N; Crowther MA; Garcia D; Hylek E; Witt DM; Ageno W;
    Pharmacotherapy; 2011 Apr; 31(4):386-93. PubMed ID: 21449627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial.
    Burmeister Getz E; Carroll KJ; Jones B; Benet LZ
    Clin Pharmacol Ther; 2016 Sep; 100(3):223-31. PubMed ID: 27037630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In favor of Coumadin over generic warfarin.
    Benson SR; Vance-Bryan K
    Am J Health Syst Pharm; 1998 Apr; 55(7):727-9. PubMed ID: 9558426
    [No Abstract]   [Full Text] [Related]  

  • 19. Reflections on generic warfarin.
    Haines ST
    Am J Health Syst Pharm; 1998 Apr; 55(7):729-33. PubMed ID: 9558427
    [No Abstract]   [Full Text] [Related]  

  • 20. Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs.
    Hottinger M; Liang BA
    Am J Law Med; 2012; 38(4):667-89. PubMed ID: 23356099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.